whitepaper
Whitepaper: Serum-free and Animal-free Research
Discover how the adoption of animal-free media/supplements can improve reproducibility in cell culture and biotherapeutic research.
List view / Grid view
Cell Therapy
whitepaper
Whitepaper: PSMA Protein in the Battle Against Cancer
The PSMA Protein is a new therapeutic hot target. In this article, learn about its growing role in the fight against prostate cancer and beyond.
article
Women in STEM with Lindsey Clarke: ‘everyone has half an hour’
For International Women's Day, Drug Target Review’s Izzy Wood recently spoke to Lindsey Clarke about her experience as a woman in STEM.
news
Stopping immune cell leakage from tumours could improve skin cancer treatment
Results show the number of specialised immune cells available for fighting skin cancer doubled when a new treatment blocked their escape from melanoma tumours.
news
New hydrogel stem cell treatment could repair injured brain tissue
The new ‘hybrid’ hydrogel allowed researchers to safely deliver stem cells to the site of a brain injury in mice.
article
Developing state-of‑the‑art CAR T-cell therapy for cancer treatment
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
article
Allogeneic CAR T-cell therapy: the future of cancer care
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
article
The next wave: going beyond CAR T cells with cell-based therapies
In this article, Dr Daniel Teper and Dr Chris Arendt explore cellular therapies for cancer that provide an alternative to chimeric antigen receptor (CAR) T-cell therapy. In these Q&As, they outline their important work in immuno-oncology.
article
The advantages of gamma-delta T-cell therapy
Here, Dr Michael Leek describes the benefits of gamma-delta T cells for cancer therapy, exploring why they present a potential alternative to other immuno-oncology platforms.
news
New study highlights lipid nanoparticles and mRNA could treat blindness
The researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible.
whitepaper
Executive summary: Scale-up strategies for late-stage cell therapies
Discover how Catalent can help you achieve efficiencies and develop a robust, reproducible manufacturing plan for late-stage and commercial launch.
news
Novel cancer vaccine simultaneously kills and prevents brain cancer
US researchers develop a dual-action cell therapy engineered to eliminate established tumours and train the immune system to eradicate primary tumour and prevent cancer’s recurrence.
news
Life-saving approach may overcome persistent obstacles to cell transplantation and immunotherapy
In their study, researchers duped antibodies with a decoy to prevent rejection of transplanted cells.
article
When exhausted, cancer-fighting T cells may switch sides
Using flow cytometry, Dr Greg Delgoffe and Dr Paolo Vignali highlight that low oxygen environment of tumours can prompt exhausted T cells to suppress the immune system instead of combating cancer.
article
Five recent cell and gene therapy discoveries
This article highlights five of the latest findings using cell and gene therapy techniques that could be used in the development or design of new therapies.
